https://www.prnewswire.com/news-releases/abbvie-expands-immunology-portfolio-in-the-us-with-fda-approval-of-skyrizi-risankizumab-rzaa-for-moderate-to-severe-plaque-psoriasis-300836934.html
risankizumab
Health Canada Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
https://www.newswire.ca/news-releases/health-canada-approves-skyrizi-tm-risankizumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-852708327.html
First global regulatory approval of SKYRIZI (risankizumab) in Japan
https://www.biospectrumasia.com/news/28/13108/abbvie-gets-the-first-global-regulatory-approval-of-skyrizi-in-japan.html
AbbVie Announces First Regulatory Approval of SKYRIZI (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis
https://www.prnewswire.com/news-releases/abbvie-announces-first-regulatory-approval-of-skyrizi-risankizumab-for-the-treatment-of-plaque-psoriasis-generalized-pustular-psoriasis-and-erythrodermic-psoriasis-and-psoriatic-arthritis-in-japan-300818288.html
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
https://clinicaltrials.gov/ct2/show/NCT03671148?type=Intr&cond=Psoriasis&lupd_s=03%2F08%2F2019&lupd_d=14
Condition : Psoriatic Arthritis
Interventions : Biological: placebo for rizankizumab; Biological: risankizumab
Sponsor : AbbVie
Recruiting
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
NCT03671148
Fri, 14 Sep 2018 12:00:00 EDT
Last Update Posted: 03/22/19 09:27AM